Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea
31 juil. 2018 04h00 HE
|
Helsinn Healthcare S.A.
Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea CINV is one of the most common and distressing side effects of cancer chemotherapyIncluded as a treatment option...